Axilium Capital

Overview

Axilium Capital is a Swedish venture capital firm established in 2018, specializing in early-stage investments in technology and life sciences sectors. The firm is committed to identifying and supporting innovative startups that have the potential to make a significant impact in their respective industries. Axilium Capital's investment approach is characterized by a hands-on partnership with entrepreneurs, providing not only financial resources but also strategic guidance to foster growth and success. The firm's portfolio encompasses a diverse range of companies across various industries, including biotech, medtech, software, semiconductor, advanced materials, e-health, virtual reality, artificial intelligence, internet of things, analytics, healthcare, consumer goods, business services, and more. This broad sector focus reflects Axilium Capital's dedication to nurturing innovation and driving progress in multiple fields. Axilium Capital's investment strategy spans multiple stages, from pre-seed to late-stage investments, including series A, series B, growth, and pre-IPO rounds. This comprehensive approach enables the firm to support companies at different phases of their development, ensuring they receive the appropriate resources and expertise to achieve their objectives. The firm's geographical focus includes Sweden, Norway, Denmark, Finland, Germany, United Kingdom, United States, Canada, France, Netherlands, Switzerland, Belgium, Austria, Italy, Spain, Portugal, Poland, Czech Republic, Hungary, and Romania, reflecting its commitment to fostering innovation on a global scale.

Investment Focus

• Innovative technology or life sciences startups with high growth potential
• Strong and experienced management teams
• Scalable business models
• Clear path to profitability
• Alignment with Axilium Capital's investment philosophy and values

Portfolio Companies